Stanford University Microbiome Bank
NCT07625059 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2026-06-04
Summary
This protocol establishes a centralized stool donor bank and research platform to support microbiota transplantation therapy (MTT) for microbiota-mediated diseases. The study will characterize donor microbiome, metabolite, immune, and dietary profiles.
Conditions
- Healthy Adult Participants
Interventions
- OTHER
-
Microbiome bank
This is an observational study with no interventions.
Sponsors & Collaborators
-
Kepner Microbiome Fund
collaborator UNKNOWN -
Mischa Deeter Research Fund
collaborator UNKNOWN -
GI Diseases Fund
collaborator UNKNOWN -
Sean Spencer
lead OTHER
Principal Investigators
-
Sean Spencer, MD, PhD · Stanford University
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-08-01
- Primary Completion
- 2027-08-01
- Completion
- 2027-08-01
Countries
- United States
Study Locations
More Related Trials
-
Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation
NCT03529825 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Investigating Cytokine Genes of Stem Cell Donors
NCT00353821 ·Status: COMPLETED
-
Distribution of Biospecimens From Biorepositories/Biobanks for Research Use
NCT03884400 ·Status: WITHDRAWN
-
Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.
NCT01165762 ·Status: UNKNOWN ·Phase: PHASE1
-
Registry on Salvage Antiviral Treatment for Patients Experiencing ADV and / or CMV Reactivation Post Allogeneic HSCT
NCT02873325 ·Status: TERMINATED
-
Survey of Severe Infections by Gram Negative Bacteria in Patients Submitted to Stem Cell Transplant
NCT02088840 ·Status: COMPLETED
-
Immune Response to Vaccinations in Hematopoietic Stem Cell Transplant Recipients
NCT03659773 ·Status: COMPLETED ·Phase: NA
-
Intestinal Microbiome-based Research for the Prevention of Acute GVHD
NCT05808985 ·Status: UNKNOWN ·Phase: PHASE2
-
Microfluidics and Transcriptomics in Post Solid Organ Transplant Patients
NCT02776111 ·Status: TERMINATED
-
Biomarkers in Transplant Recipients to Improve Outcomes
NCT01163578 ·Status: RECRUITING
-
Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs
NCT00319657 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
NCT06649201 ·Status: RECRUITING
-
Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant
NCT02526329 ·Status: WITHDRAWN ·Phase: PHASE1
-
Response to SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy Patients
NCT04723706 ·Status: COMPLETED
-
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
NCT03159364 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
NCT05554068 ·Status: RECRUITING ·Phase: PHASE2
-
Alternate Donor Study of Pre-Emptive Cellular Therapy
NCT01220895 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study on the Impact of Covid-19 Vaccine on Allogeneic Hematopoietic Stem Cell Transplantation
NCT05587881 ·Status: WITHDRAWN
-
Generation of an Induced Pluripotent Stem (iPS) Cell Bank Immune Matched to a Majority of the US Population
NCT03434808 ·Status: TERMINATED ·Phase: NA
-
Clinical Performance of SE-SPTM-PCR in Detecting Hcmv-miR-UL22A-5p After Hematopoietic Stem Cell Transplantation
NCT07181330 ·Status: COMPLETED
-
T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant
NCT00986557 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Performance Evaluation of the NeuMoDx™ EBV Quant Assay 2.0 in Immunocompromised Transplant Patients
NCT06681025 ·Status: COMPLETED
-
A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells
NCT06798298 ·Status: RECRUITING
-
Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation
NCT02227641 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study
NCT05135650 ·Status: TERMINATED ·Phase: PHASE1